Annual financial statement
Page 1
Bioventix plc (“Bioventix” or “the Company”) Results for the year ended 30 June 2026 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinitymonoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2026. Highlights: Revenue down 0.8% to £13.0 million (2025: £13.1 million)Profit before tax up 1% to £10.2 million (2025: £10.1 million) Revenue £13.3m and PBT 10.5m on a constant currency basis (at average exchange rates for 2024/25)Tau/neuro royalties increased three-fold to £257k (2025: £75k) 5 Tau SMAs being produced at scale, 2 eMTBR SMAs moving into production Q4 CY 2026Cash at year end of £5.3 million (30 June 2025: £5.1 million) Second interim dividend of 80p per share (2025: 80p) total dividends 150p per share (2025: 150p) Introduction Our Technology and Business Model Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved testperformance compared to other available antibodies. Most of our antibodies are used on blood-testing machines installed in hospitals and laboratories around the world. Bioventix creates antibodies using our SMA technology for supply to diagnostic companies forsubsequent integration into reagent packs used on blood-testing machines in clinical settings across the world. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such asRoche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are currently used to help diagnose many different conditions including, amongst others, heart disease, thyroidfunction, fertility, infectious disease and cancer. Testosterone is an example of a blood test where a Bioventix SMA facilitated an improved test. In 2003, it became clear that testosterone tests performed on automated IVD platforms were deficient. Whilst the higherlevels of testosterone in healthy adult males were accurately reported, the lower levels of testosterone in pre- pubescent boys and women were inaccurately reported. In 2005, Bioventix created an antibody calledtesto3.6A3 which was evaluated by customers during 2006. Evaluations were successful and following the necessary regulatory approvals, the first testosterone assays based on testo3.6A3 were launched in 2009. Anumber of IVD companies still use this antibody for tests that more accurately measure lower levels of testosterone. Over the past 20 years, we have created and supplied approximately 30 different SMAs that are used by IVDcompanies around the world in their blood test panels for diagnosis of various conditions including cardiac, thyroid, fertility and vitamin D deficiency. We currently sell a total of 15-20 grams of purified physical antibodyper year which accounts for 25-33% of our annual revenue. In addition to revenues from these physical antibody supplies, the sale by our customers of diagnostic products (based on our antibodies) to theirdownstream end-users attracts a modest percentage royalty payable to Bioventix. These downstream royaltiescurrently account for the remaining 67-75% of our annual revenue. Bioventix adopts different commercial and scientific approaches when creating new antibodies. The first is own-risk antibody creation projects prompted by our evaluation of the need and commercial use opportunity for an antibody; this provides Bioventix with the complete freedom to commercialise the antibodies produced. Thesecond approach is contract antibody creation projects prompted by, and in partnership with, customers whosupply materials, know-how and funding to create antibodies that can only be commercialised with the partner company. More recently our third approach, to product development, has been through collaborative research.In the increasingly significant field of neurological conditions, this approach has become important and is exemplified by our work on Alzheimer’s blood tests with the University of Gothenburg. Considerable progresshas been made in the treatment of Alzheimer’s patients with newly approved and licensed therapeutics. The consequent need and opportunity for diagnostics in this area is substantiated by the activity of, and considerableinvestment being made by, major pharmaceutical companies in the specialism and there are currently 350 drugs undergoing trial with 20% of those Phase III trials. We anticipate that collaboration with academic researcherswill play an increasingly important role in the identification and subsequent creation of SMAs for use in diagnosing neurological conditions and the development by IVD manufacturers of neurological panels of assaysfor their customers. In all cases, after initiation of a new project, it takes around a year for our scientists to create a panel of purified antibodies for evaluation by our customers or academic partners. The evaluation process at their laboratoriesgenerally requires the fabrication of prototype tests which can be compared to other tests, for example the customer’s existing commercial test or perhaps another “gold standard” method, on the assay machine platformbeing considered. The process of subsequent development thereafter by our customers can take many years
Page 2
before registration or approval from the relevant authority. Only once approval from the US Food and DrugAdministration (FDA) or EU authorities is obtained can products then be sold to the benefit of the customers, and of course Bioventix, through the agreed sales royalty. This does mean that there is a lead time of 4-10 yearsbetween our own research work and the receipt by Bioventix of royalty revenue from product sales. However, because of the resource required to gain such approvals, after having achieved approval for an accuratediagnostic test using a Bioventix antibody, there is a natural incentive for continued antibody use. This results in a significant barrier to entry for potential replacement antibodies which would require at least partial repetition ofthe approval process arising on a change from one antibody to another. This barrier to antibody replacement arises from a combination of factors driven by the clinical criticality of the test and the potential consequences ofmaking such a change which include the time and cost to register any changes required to validate the performance of the replacement antibody. Another consequence of the lengthy approval process is that the revenue for the current accounting period isderived largely from antibodies created many years ago. In the fast-moving field of neurological assays, this dynamic has evolved with the relatively rapid launch of “research use only” (RuO) products not only by our historic customers but also by newer high sensitivity platformcompanies who have now become customers. 2025/2026 Financial Results Bioventix continues to evolve from the generation of value from our historical product portfolio of core antibodiesinto a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases. Total revenues for the year of £13 million were similar to theprevious reporting period (2024/25: £13.1 million) and slightly ahead of market expectations. Profits after tax at £7.6 million were also similar to last year (2024/25: £7.6million) and again ahead of expectation. Cash balancesat the year-end were £5.3 million (30 June 2025 £5.1 million). These results reflect the growing importance of neurology in our product portfolio with royalty revenues from our Tau/neuro SMAs increasing from £75k in 2024/25 to £257k for 2025/26. The three-fold increase in Tau/neuroroyalty revenues has been driven by increased use of our antibodies in research use only (RuO) assays at three of the newer high sensitivity platform companies active in Alzheimer’s diagnostics. We expect these royalties toincrease further as our historic customer base of established IVD companies (e.g. Roche, Siemens, Beckman, Abbott, Mindray, Fujirebio) launch p-Tau217 assays, not only RuO assays in research settings but also, in time,assays for routine clinical use on their platforms, we believe some of these assays will feature Bioventix SMAs. Within our historic core business, vitamin D continues to be very important and sales of vitD3.5H10 decreased by 4% to £6.35 million due to a difficult downstream market, in particular in China. We have explained previously that important aspects of the Chinese commercial landscape are changing. The“China First” policy, Chinese Central Government procurement strategy and increased activity from local Chinese antibody suppliers remain significant factors. Our sales to Chinese customers have reduced slightly in2025/26 and, whilst we would anticipate a continuing diminution in revenue from these customers, we anticipate China will continue to be a significant source of revenue in future years. Troponin sales for the year were c.£1.4 million in line with 2024/25 and we have not yet seen any impact from anincreased use of troponin testing as part of monitoring patients who had previously suffered a cardiac event. As previously disclosed, Siemens troponin revenues will terminate for contractual reasons in June 2032. The sales portfolio mix for 2025/26 appears below together with the increase/decrease (+/-) in sales comparedto the previous year 2024/25:
Page 3
In addition to the impact of external factors such as dynamics in the Chinese market there will also be changesreflecting our historic commercial structure and success built on supply and royalty contracts with lifetimes of between 10 and 15 years from the first use of our antibodies by our customers. One such contract for aprogesterone antibody terminated in 2025/26 and the annual sales of approximately £400k will therefore not be in our revenue in future. We estimate that 50-60% of our total sales are directly linked to US Dollars either directly through physicalproduct pricing in US Dollars or indirectly linked to US Dollars through royalties based on downstream US Dollar sales. The remainder of the currency split is dominated by Euros and important Asian currencies. Currencyeffects in the financial year reduced turnover on a constant currency basis by approximately £300k. In addition, there was also a gain of approximately £62k due to favourable currency movements between invoicing andsettlement. Our view continues to be that hedging mechanisms would not, in the longer term, add value and may have the potential to add risk to our business. Consequently, future movements in exchange rates maytherefore affect our Sterling revenues. Cash Flows and Dividends The business generated c £8 million of cash during the year of which almost all was returned to shareholders asdividends. The business retained cash balances at the year-end of £5.3 million and royalties received, in respect of the second half of 2025/26, during July to September of 2026 have added to this balance. In consideration of our established dividend policy and the available cashflows, the Board is pleased toannounce a second interim dividend of xx pence per share which, when added to the first interim dividend of 70 pence per share makes a total of 150 pence per share for the current year. Accordingly, a dividend of 80 pence per share will be paid in November 2026. The shares will be marked ex-dividend on 5 November 2026 and the dividend will be paid on 20 November 2026 to shareholders on the register at close of business on 6 November 2026. Research and Future Developments A significant scientific development during the year has been the emergence of “eMTBR-Tau” immunoassays from Alamar Biosciences and Spear Bio. Whilst p-Tau217 tracks AD through early amyloid pathology and laterTau tangle pathology, eMTBR-Tau is more specific for later stage disease caused by Tau tangles. eMTBR-Tau assays could therefore be useful to confirm clinical assessment of cognition in later stage disease. In addition,eMTBR-Tau could be helpful in ruling out candidates for clinical trials and future therapeutic options. We believe we have made excellent eMTBR SMAs and are delighted to have played our part in the eMTBR-Tau discovery process. The overall response from customers to our various Tau evaluation samples of SMAs supplied for RuO assayshas been positive and we are encouraged by our growing footprint in these areas. We have previously described how neuroscientists use the Amyloid, Tau, Neurological degeneration (“A/T/N”) framework to define the AD pathway and the blood-based biomarker tests being developed to supplement orreplace more expensive, low throughput brain scans. Our footprint in the field is described in the table below. Alzheimer’s SMAs commercialisation “Partners” have either launched an RuO or IVD assay or we believe have imminent plans to launch an assay that uses at least one SMA “Partners/IVD” a top 10 global IVD company “New HS” a newer high sensitivity platform company Following the success above, we now have five Tau antibodies being made at scale in our manufacturing facility. In addition to this, two newer eMTBR antibodies are currently moving into large scale production. This
Page 4
demonstrates the significant momentum in our neurology opportunity. In addition to the Tau/neuro commercial developments above, our research continues and we are making new antibodies that could feature in additional blood tests to better assess neurological diseases. In addition toAlzheimer’s disease, we have projects running in the field of vascular dementia, rarer dementias and peripheral neuropathies. Bioventix has been working with the University of Gothenburg since early 2020 to create new antibodies to Tauand to develop prototype assays for use in Alzheimer’s disease. This collaboration has been a key to our growing success in this field, and we plan to continue our work with this world-leading research facility into thefuture. The view of many neurological opinion leaders, shared by our IVD customers, is that blood-testing machines will soon offer a panel of new neurological tests that will reveal information about patient brain healthwhich will be useful for screening and therapy monitoring purposes. Whilst not of the same potential value as our activities in neurology diagnostics, we have continued our work on sewage contamination of rivers and lakes. We hope to have a lateral flow assay for paracetamol before the yearend which is intended to calibrate to 0.1-1.0% of raw sewage contamination in “fresh” waters. We plan to work with volunteer groups to conduct field trials aimed at better understanding the link between paracetamol levelsand Escherichia coli (“E.coli”), a significant concern for sewage contamination in waterways. Pre-Diagnostics (in Oslo) and their clinical collaborators have two amyloid beta assays based on Bioventix antibodies available for research use. A current focus for Pre-Diagnostics is ARIA (amyloid related imagingabnormality) which is an important side-effect of new anti-amyloid drugs for Alzheimer’s. Pre-Diagnostics assays relate to amyloid metabolism and could help screen for ARIA vulnerable patients, before or duringtreatment. Our pyrene lateral flow system for industrial pollution biomonitoring is proceeding steadily as planned. We plan to continue field trials with firefighters during 2027. Future Strategy Our historic core business has continued to perform well and we will strive to maintain revenues through thecontinued supply of high-quality SMAs accompanied by excellent customer service and response. We believe that any new opportunities, outside of our neurology related work, are likely to come from our new “sandwich”formats for small molecules. We have had some encouraging customer feedback from a cortisol sandwich pair and this has prompted us to create a similar sandwich format for our vitamin D product offering. The next few years will be exciting for our emerging Tau/neuro SMAs. We plan to develop our neurologicalpipeline further through our on-going collaboration with the University of Gothenburg. In addition, as the frontier of neuroscience and the blood-based biomarker field evolves, we will seek additional opportunities that mayemerge from other collaborators in this rapidly developing area. The success of our business is closely linked to the dedication, hard work and skill of our team of scientists and support staff. We will continue to nurture and invest in the team to build both our and their skills, knowledge andcapabilities. The Bioventix Team and Facility The composition of the Bioventix team remains at 12 full-time equivalents (14 staff in total). During the year one long serving employee retired and we recruited an additional graduate. This level of stability has formed anexcellent base upon which we have been able to build our new products moving into the exciting new areas
Page 5
described above. We are very fortunate to have such a dedicated and loyal team and we are grateful to themfor their continued enthusiastic input and support. Conclusion and Outlook This year has been particularly noteworthy as our historic core business has faced some challenges indownstream markets, particularly in China. Despite these headwinds, we have delivered a marginally better set of results whilst maintaining dividend levels and a healthy cash balance, demonstrating the robustness of thebusiness. Meanwhile, our research and commercialisation of antibodies in the field of neurology have yielded significant progress. The vision of our customers for growth in this exciting field together with the performance of ourantibodies at many of our customers points to future success in this area. We expect that the year to 30 June 2027 will follow a similar pattern to this year. Revenue generation from our historic core business will be subject to headwinds and be replaced and increasingly augmented by sales fromour growing Tau and neurology portfolio of antibodies. Longer term we expect the neurology portfolio to deliver growth to offset the challenges that our legacy antibodies will continue to face. The timing of that growth isdifficult to forecast but our level of confidence in the opportunity is undiminished. P Harrison Chief Executive Officer I J Nicholson Non‐Executive Chairman For further information please contact: Bioventix plc Peter HarrisonChief Executive Officer Tel: 01252 728 001 Cavendish (NOMAD and Broker)Geoff Nash / Elysia Bough Corporate Finance Nigel Birks / Harriet Ward ECMTel: 020 7220 0500 STATEMENT OF COMPREHENSIVE INCOMEFOR THE YEAR ENDED 30 JUNE 2026 2026 2025 Note £ £
Page 6
Turnover 4 12,971,744 13,115,869 Cost of sales (1,109,210) (1,198,877) Gross profit 11,862,534 11,916,992 Administrative expenses (2,042,493) (2,051,446) Difference on foreign exchange 62,410 (170,006) Research and development tax credit 291,636 297,249 Share option charge (86,648) (89,223) Operating profit 5 10,087,439 9,903,566 Interest receivable and similar income 8 140,125 192,349 Interest payable and expenses 9 (140) - Profit before tax 10,227,424 10,095,915 Tax on profit 10 (2,612,771) (2,511,473) Profit for the financial year 7,614,653 7,584,442 Total comprehensive income for the year 7,614,653 7,584,442 The notes on pages 21 to 37 form part of these financial statements. Earnings per share: 2026 2025 Basic (pence per share) 145.74 145.27 Diluted (pence per share) 143.62 143.35 STATEMENT OF FINANCIAL POSITIONAS AT 30 JUNE 2026 2026 2025 Note £ £ Fixed assets Tangible assets 12 429,903 404,357 Investments 13 426,733 426,733
Page 7
856,636 831,090 Current assets Stocks 14 707,045 689,404 Debtors: amounts falling due within one year 15 5,998,601 6,263,980 Cash at bank and in hand 16 5,264,706 5,079,295 11,970,352 12,032,679 Creditors: amounts falling due within oneyear 17 (1,404,106) (1,312,052) Net current assets 10,566,246 10,720,627 Total assets less current liabilities 11,422,882 11,551,717 Creditors: amounts falling due after morethan one year (7,154) - Net assets 11,415,728 11,551,717 Capital and reserves Called up share capital 20 261,243 261,243 Share premium account 21 1,541,309 1,541,309 Capital redemption reserve 21 1,231 1,231 Profit and Loss Account 21 9,611,945 9,747,934 11,415,728 11,551,717 The financial statements were approved and authorised for issue by the board and were signed on its behalf on Director The notes on pages 21 to 37 form part of these financial statements.
Page 9
STATEMENT OF CHANGES IN EQUITYFOR THE YEAR ENDED 30 JUNE 2026 Called up share capital Share premium account Capital redemption reserve Profit and loss account Total equity £ £ £ £ £ At 1 July 2025 261,243 1,541,309 1,231 9,747,934 11,551,717 Comprehensive income for theyear Profit for the year - - - 7,614,653 7,614,653 Other comprehensive income forthe year - - - - - Total comprehensive income forthe year - - - 7,614,653 7,614,653 Contributions by anddistributions to owners Dividends: Equity capital - - - (7,837,290) (7,837,290) Share option charge - - - 86,648 86,648 Total transactions with owners - - - (7,750,642) (7,750,642) At 30 June 2026 261,243 1,541,309 1,231 9,611,945 11,415,728 The notes on pages 21 to 37 form part of these financial statements.
Page 11
STATEMENT OF CHANGES IN EQUITYFOR THE YEAR ENDED 30 JUNE 2025 Called up share capital Share premium account Capital redemption reserve Profit and loss account Total equity £ £ £ £ £ At 1 July 2024 260,983 1,471,315 1,231 10,269,129 12,002,658 Comprehensive income for theyear Profit for the year - - - 7,584,442 7,584,442 Other comprehensive income forthe year - - - - - Total comprehensive income forthe year - - - 7,584,442 7,584,442 Contributions by anddistributions to owners Dividends: Equity capital - - - (8,194,860) (8,194,860) Shares issued during the year 260 69,994 - - 70,254 Share option charge - - - 89,223 89,223 Total transactions with owners 260 69,994 - (8,105,637) (8,035,383) At 30 June 2025 261,243 1,541,309 1,231 9,747,934 11,551,717 The notes on pages 21 to 37 form part of these financial statements.
Page 13
STATEMENT OF CASH FLOWSFOR THE YEAR ENDED 30 JUNE 2026 2026 2025 £ £ Cash flows from operating activities Profit for the financial year 7,614,653 7,584,442 Adjustments for: Depreciation of tangible assets 57,023 92,829 Interest paid 140 - Interest received (140,125) (192,349) Taxation charge 2,612,771 2,511,473 (Increase) in stocks (17,641) (74,059) Decrease/(increase) in debtors 261,853 (34,105) Increase/(decrease) in creditors 223,196 (98,131) Corporation tax (paid) (2,744,203) (2,847,536) Share option charge 86,648 89,223 Net cash generated from operating activities 7,954,315 7,031,788 Cash flows from investing activities Purchase of tangible fixed assets (71,599) (19,189) Interest received 140,125 192,349 Net cash from investing activities 68,526 173,160 Cash flows from financing activities Issue of ordinary shares - 70,254 Interest paid 140 - Dividends paid (7,837,290) (8,194,860) Net cash used in financing activities (7,837,430) (8,124,606) Net increase/(decrease) in cash and cash equivalents 185,411 (919,658) Cash and cash equivalents at beginning of year 5,079,295 5,998,953 Cash and cash equivalents at the end of year 5,264,706 5,079,295 Cash and cash equivalents at the end of year comprise: Cash at bank and in hand 5,264,706 5,079,295
Page 14
5,264,706 5,079,295 The notes on pages 21 to 37 form part of these financial statements.
Page 16
ANALYSIS OF NET DEBTFOR THE YEAR ENDED 30 JUNE 2026 At 1 July 2025 Cash flows New finance leases At 30 June 2026 £ £ £ £ Cash at bank and in hand 5,079,295 185,411 - 5,264,706 Finance leases due within 1 year - - (3,816) (3,816) Finance leases due in more that one year (7,154) (7,154) 5,079,295 185,411 (10,970) 5,253,736 The notes on pages 21 to 37 form part of these financial statements.
Page 18
1. NOTES TO THE FINANCIAL STATEMENTSFOR THE YEAR ENDED 30 JUNE 2026 General information Bioventix Plc (04923945) is a public limited company registered in England and Wales. The RegisteredOffice is 27‐28 Eastcastle Street, London, W1W 8DH. 2. Accounting policies 2.1 Basis of preparation of financial statements The financial statements have been prepared under the historical cost convention unless otherwisespecified within these accounting policies and in accordance with Financial Reporting Standard 102,the Financial Reporting Standard applicable in the UK and the Republic of Ireland (September 2024)(‘FRS 102’) and the Companies Act 2006. The company has elected to early adopt the amendments to FRS102 arising from the PeriodicReview 2024, as incorporated into the September 2024 edition of FRS102. These amendments areotherwise effective for accounting periods beginning on or after 1 January 2026. The amendments have been applied in accordance with the applicable transitional provisions ofFRS102. The adoption of the amendments has not had a material impact on the amountsrecognised in the financial statements nor have they impacted the comparative year.The financial statements have been prepared on a going concern basis. The directors haveassessed the company’s ability to continue as a going concern and have no material uncertainties in this regard. The figures in the accounts have been rounded to the nearest £1. The preparation of financial statements in compliance with FRS 102 requires the use of certaincritical accounting estimates. It also requires management to exercise judgment in applying theCompany's accounting policies (see note 3). The following principal accounting policies have been applied: 2.2 Revenue Revenue is recognised when control of the promised goods or services is transferred to thecustomer in an amount that reflects the consideration to which the company expects to be entitledin exchange for those goods or services. Revenue excludes value added tax and is stated net ofdiscounts, rebates and other sales taxes. The company applies the five-step model set out inSection 23 of FRS 102 to determine when revenue should be recognised. The company recognises revenue by:1. Identifying the contract with a customer;2. Identifying the performance obligations within the contract;3. Determining the transaction price;4. Allocating the transaction price to the performance obligations; and5. Recognising revenue when, or as, the performance obligations are satisfied. Licence fees Annual licence fee revenue is recognised, in full, when the control of the licence is given over to thelicensee. Royalties Royalties are accrued over the period to which they relate and revenue is recognised based upon returns and notifications received from customers. In the event that subsequent adjustments to royalties areidentified they are recognised in the period in which they are identified. Direct sales Direct sales are generally recognised at the date of dispatch unless contractual terms with customersstate that risk and title pass on delivery of goods, in which case revenue is recognised on delivery. R&D income Subcontracted R&D income is recognised based upon the stage of completion at the year‐end.
Page 20
2.3 Foreign currency translation Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchangerates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate.Non‐monetary items measured at historical cost are translated using the exchange rate at the date ofthe transaction and non‐monetary items measured at fair value are measured using the exchangerate when fair value was determined. 2.4 Right of use assets The company recognises a right-of-use asset and a corresponding lease liability at thecommencement date of a lease. The right-of-use asset is initially measured at cost, comprising: the amount of the initial measurement of the lease liability; any lease payments made at or before the commencement date less any leaseincentives received; any initial direct costs incurred; and an estimate of costs to be incurred in dismantling and removing the underlying asset orrestoring the site on which it is located, where applicable. Subsequent to initial recognition, right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment losses. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease termand the useful economic life of the underlying asset. Where ownership of the underlying asset transfers to the company by the end of the lease term, or the cost of the right-of-use assetreflects that the company will exercise a purchase option, depreciation is charged over the useful economic life of the underlying asset. 2.5 Interest income Interest income is recognised in profit or loss using the effective interest method. 2.6 Finance costs Finance costs are charged to profit or loss over the term of the debt using the effective interestmethod so that the amount charged is at a constant rate on the carrying amount. Issue costs areinitially recognised as a reduction in the proceeds of the associated capital instrument. 2.7 Pensions Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is apension plan under which the Company pays fixed contributions into a separate entity. Once thecontributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paidare shown in accruals as a liability in the Statement of financial position. The assets of the plan areheld separately from the Company in independently administered funds. 2.8 Current and deferred taxation Current and deferred tax are recognised as an expense or income in the Statement ofComprehensive Income, except when they relate to items credited or debited directly to equity, inwhich case the tax is also recognised directly in equity. The current income tax charge is calculatedon the basis of tax rates and laws that have been enacted or substantively enacted by the reportingdate in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but notreversed by the reporting date, except that: The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Page 21
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect ofbusiness combinations, when deferred tax is recognised on the differences between the fair values ofassets acquired and the future tax deductions available for them and the differences between the fairvalues of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determinedusing tax rates and laws that have been enacted or substantively enacted by the reporting date. 2.9 Research and development Research and development expenditure is written off in the year in which it is incurred. 2.10 Tangible fixed assets Tangible fixed assets under the cost model are stated at historical cost less accumulateddepreciation and any accumulated impairment losses. Historical cost includes expenditure that isdirectly attributable to bringing the asset to the location and condition necessary for it to be capableof operating in the manner intended by management. Land is not depreciated. Depreciation on other assets is charged so as to allocate the cost of assetsless their residual value over their estimated useful lives, as follows: Freehold property ‐ 2% straight line Plant & machinery ‐ 15% straight line Motor Vehicles ‐ 25% straight line Fixtures & Fittings ‐ 15% straight line Office equipment ‐ 25% straight line Right of use assets - 33% straight line 2.11 Valuation of investments Investments in unlisted company shares, whose market value can be reliably determined, areremeasured to market value at each reporting date. Gains and losses on remeasurement arerecognised in the Statement of comprehensive income for the period. Where market value cannot bereliably determined, such investments are stated at historic cost less impairment.
Page 23
2.12Stocks Stocks are stated at the lower of cost and net realisable value, being the estimated selling price lesscosts to complete and sell. Cost includes all direct costs and an appropriate proportion of fixed andvariable overheads. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carryingamount is reduced to its selling price less costs to complete and sell. The impairment loss isrecognised immediately in profit or loss. 2.13 Debtors Short‐term debtors are measured at transaction price, less any impairment. Loans receivable aremeasured initially at fair value, net of transaction costs, and are measured subsequently at amortisedcost using the effective interest method, less any impairment. 2.14 Cash and cash equivalents Cash is represented by cash in hand and deposits with financial institutions repayable withoutpenalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments thatmature in no more than twelve months from the date of acquisition and that are readily convertible toknown amounts of cash with insignificant risk of change in value. In the Statement of cash flows, cash and cash equivalents are shown net of bank overdrafts that arerepayable on demand and form an integral part of the Company's cash management. 2.15 Creditors Short‐term creditors are measured at the transaction price. Other financial liabilities, including bankloans, are measured initially at fair value, net of transaction costs, and are measured subsequently atamortised cost using the effective interest method. 2.16 Provisions for liabilities Provisions are recognised when an event has taken place that gives rise to a legal or constructiveobligation, a transfer of economic benefits is probable and a reliable estimate can be made. Provisions are measured as the best estimate of the amount required to settle the obligation, takinginto account the related risks and uncertainties. Increases in provisions are generally charged as an expense to profit or loss. 2.17 Financial instruments The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS102 to all of its financial instruments. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initiallymeasured at their transaction price including transaction costs and are subsequently carried at theiramortised cost using the effective interest method, less any provision for impairment, unless thearrangement constitutes a financing transaction, where the transaction is measured at the present
Page 25
value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cashequivalents, trade and most other receivables due within the operating cycle fall into this category offinancial instruments. Financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractualarrangements entered into. An equity instrument is any contract that evidences a residual interest inthe assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other creditors, bank loans and other loans areinitially measured at their transaction price after transaction costs. When this constitutes a financingtransaction, the debt instrument is measured at the present value of the future payments discountedat a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest ratemethod. Trade payables are obligations to pay for goods and services that have been acquired in the ordinarycourse of business from suppliers. Trade payables are classified as current liabilities if the payment isdue within one year. If not, they represent non‐current liabilities. Trade payables are initiallyrecognised at their transaction price and subsequently are measured at amortised cost using theeffective interest method. Discounting is omitted where the effect of discounting is immaterial. 2.18 Dividends Equity dividends are recognised when they become legally payable. Interim equity dividends arerecognised when paid. Final equity dividends are recognised when approved by the shareholders atan annual general meeting. 2.19Employee benefits‐share‐based compensation The Company operates an equity‐settled, share‐based compensation plan. The fair value of theemployee services received in exchange for the grant of the options is recognised as an expenseover the vesting period. The total amount to be expensed over the vesting period is determined byreference to the fair value of the options granted. At each balance sheet date, the Company willrevise its estimates of the number of options expected to be exercisable. It will recognise the impactof the revision of original estimates, if any, in the profit and loss account, with a correspondingadjustment to equity. The proceeds received net of any directly attributable transaction costs arecredited to share capital (nominal value) and share premium when the options are exercised.
Page 27
3. Judgments in applying accounting policies and key sources of estimation uncertainty In the application of the Company's accounting policies (as described in note 2), management is requiredto make judgments, estimates and assumptions. These estimates and underlying assumptions arereviewed on an ongoing basis. Carrying value of unlisted investments The Company holds two unlisted investments in companies carrying out research in identifyingbiomarkers for diagnosing health conditions. The directors have continued to review the progress of thisresearch over the last year. In common with much scientific research, there is uncertainty, both in relation to the science and to thecommercial outcomes, and no information to reliably calculate a fair value for these investments. An impairment provision against the value of the investment in shares of CardiNor AS was made in theyear to 30 June 2024. The carrying value of the other investment in Pre Diagnostics will continue to be the historic cost of£426,733.(2025: £426,733) Royalty revenue accrual The Company is notified and receives royalty revenue from one customer on a calendar year basisannually in arrears; it is therefore necessary to estimate this revenue for the first six months of thecalendar year and to process an accrual of £200,000 (2025: £323,000) in respect of it. 4. Turnover An analysis of turnover by class of business is as follows: 2026 2025 £ £ Product revenue and R&D income 4,138,064 4,163,845 Royalty and licence fee income 8,833,680 8,952,024 12,971,744 13,115,869 2026 2025 £ £ United Kingdom 742,785 798,661 Other EU 1,507,180 1,640,397 Rest of the world 10,721,779 10,676,811 12,971,744 13,115,869
Page 29
5. Operating profit The operating profit is stated after charging: 2026 2025 £ £ Depreciation of tangible fixed assets 57,023 92,829 Fees payable to the Company's auditor for the audit of the Company'sannual financial statements 36,000 34,500 Exchange differences (62,410) 170,006 Research and development costs 1,458,180 1,486,245 6. Employees Staff costs, including directors' remuneration, were as follows: 2026 2025 £ £ Wages and salaries 1,184,678 1,152,613 Social security costs 155,384 147,097 Share option charge 86,648 89,223 Cost of defined contribution scheme 95,876 91,942 1,522,586 1,480,875 The average monthly number of employees, including the directors, during the year was as follows: 2026 2025 No. No. Management and administration 4 5 Scientific 12 11 16 16
Page 31
7. Directors' remuneration 2026 2025 £ £ Directors' emoluments 510,316 523,004 Company contributions to defined contribution pension schemes 55,328 47,984 565,644 570,988 During the year retirement benefits were accruing to 2 directors (2025 ‐ 2) in respect of definedcontribution pension schemes. The highest paid director received remuneration of £367,368 (2025 ‐ £317,845). The value of the Company's contributions paid to a defined contribution pension scheme in respect of thehighest paid director amounted to £51,431 (2025 ‐ £44,498). 8. Interest receivable 2026 2025 £ £ Other interest receivable 140,125 192,349 9. Interest payable and similar expenses 2026 2025 £ £ Finance leases and hire purchase contracts 140 - 140 -
Page 33
10. Taxation 2026 2025 £ £ Corporation tax Current tax on profits for the year 2,580,341 2,554,501 Adjustments in respect of previous periods 28,904 (25,071) Total current tax 2,609,245 2,529,430 Deferred tax Origination and reversal of timing differences 3,526 (17,957) Taxation on profit on ordinary activities 2,612,771 2,511,473 Factors affecting tax charge for the year The tax assessed for the year is higher than (2025 ‐ lower than) the standard rate of corporation tax inthe UK of 25% (2025 ‐ 25%). The differences are explained below: 2026 2025 £ £ Profit on ordinary activities before tax 10,227,424 10,095,915 Profit on ordinary activities multiplied by standard rate of corporation tax inthe UK of 25% (2025 ‐ 25%) 2,556,856 2,523,979 Effects of: Expenses not deductible for tax purposes, other than goodwill amortisationand impairment 24,745 2,789 Capital allowances for year in excess of depreciation (2,177) 16,707 Adjustments to tax charge in respect of prior periods 28,904 (25,071) Changes in provisions leading to an increase (decrease) in the tax charge 917 3,031 Share based payments - 7,995 Deferred tax movement 3,526 (17,957) Total tax charge for the year 2,612,771 2,511,473 Factors that may affect future tax charges There were no factors that may affect future tax charges.
Page 34
11. Dividends 2026 2025 £ £ Dividends paid 150 pence per share (2025:157 pence per share) 7,837,290 8,194,860 7,837,290 8,194,860
Page 36
12. Tangible fixed assets Freehold property Plant & Machinery Motor Vehicles Fixtures & Fittings Office Equipment £ £ £ £ £ Cost or valuation At 1 July 2025 475,000 509,302 13,090 410,551 21,191 Additions - 45,323 - - 13,940 At 30 June 2026 475,000 554,625 13,090 410,551 35,131 Depreciation At 1 July 2025 171,000 459,220 13,090 362,239 19,228 Charge for the year onowned assets 7,125 20,352 - 25,324 2,280 Charge for the year onfinanced assets - - - - - At 30 June 2026 178,125 479,572 13,090 387,563 21,508 Net book value At 30 June 2026 296,875 75,053 - 22,988 13,623 At 30 June 2025 304,000 50,082 - 48,312 1,963
Page 38
Right of use assets Total £ £ Cost or valuation At 1 July 2025 - 1,429,134 Additions 23,306 82,569 At 30 June 2026 23,306 1,511,703 Depreciation At 1 July 2025 - 1,024,777 Charge for the year on owned assets - 55,081 Charge for the year on financed assets 1,942 1,942 At 30 June 2026 1,942 1,081,800 Net book value At 30 June 2026 21,364 429,903 At 30 June 2025 - 404,357 The Right of use Assets are depreciated in line with the length of the lease. The net book value of land and buildings may be further analysed as follows: 2026 2025 £ £ Freehold 296,875 304,000 296,875 304,000
Page 40
13. Fixed asset investments Unlisted Investments £ Cost or valuation At 1 July 2025 610,039 At 30 June 2026 610,039 Impairment At 1 July 2025 183,306 At 30 June 2026 183,306 Net book value At 30 June 2026 426,733 At 30 June 2025 426,733 14. Stocks 2026 2025 £ £ Finished goods and goods for resale 707,045 689,404 15. Debtors 2026 2025 £ £ Trade debtors 1,425,733 1,031,762 Other debtors 26,240 29,855 Prepayments and accrued income 4,529,708 5,181,917 Deferred taxation 16,920 20,446 5,998,601 6,263,980
Page 41
16. Cash and cash equivalents 2026 2025 £ £ Cash at bank and in hand 5,264,706 5,079,295 Cash is held in both current accounts and interest earning deposit accounts with UK High Street Banks; such deposits are made for varying terms. 17. Creditors: Amounts falling due within one year 2026 2025 £ £ Trade creditors 271,004 77,948 Corporation tax 701,752 836,710 Other taxation and social security 34,728 32,425 Obligations under finance lease and hire purchase contracts 3,816 - Accruals and deferred income 392,806 364,969 1,404,106 1,312,052
Page 43
18. Creditors: Amounts falling due after more than one year 2026 2025 £ £ Net obligations under finance leases and hire purchase contracts 7,154 - 7,154 - 19. Deferred taxation 2026 2025 £ £ At beginning of year 20,446 2,489 (Charged)/credited to profit or loss (3,526) 17,957 At end of year 16,920 20,446 The deferred tax asset is made up as follows: 2026 2025 £ £ Accelerated capital allowances 16,920 20,446 16,920 20,446
Page 45
20. Share capital 2026 2025 £ £ Allotted, called up and fully paid 5,224,860 (2025 ‐ 5,224,860) Ordinary shares of £0.05 each 261,243 261,243 The holders of ordinary shares are entitled to receive dividends as declared and are entitled to one voteper share at meetings of the Company. All ordinary shares rank equally with regard to the Company'sresidual assets. 21. Reserves Share premium account The share premium reserve contains the premium arising on issues of equity shares, net of issueexpenses. Capital redemption reserve The capital redemption reserve arose on the buy‐back of shares by the company. Profit & loss account The profit and loss reserve represents cumulative profits or losses, net of dividends paid and otheradjustments.
Page 47
22. Share‐based payments During the year the Company operated 2 share option schemes; an Approved EMI Share OptionScheme and an Unapproved Share Option Scheme to incentivise employees. The Company has applied the requirements of FRS 102 Section 26 Share‐based Payment to all theoptions granted under both schemes. The terms for granting share options under both schemes are thesame and provide for an option price equal to the market value of the Company's shares on the date ofthe grant and for the Approved EMI Share Option Scheme this price is subsequently agreed with HMRCShares and Assets Valuation Division. The contractual life of an option under both schemes is 10 years from the date of grant. Options grantedbecome exercisable on the third anniversary of the date of grant. Exercise of an option is normallysubject to continued employment, but there are also considerations for good leavers. All share basedremuneration is settled in equity shares. The number and weighted average exercise price of share options during the year are as follows: Weighted average exercise price (pence) 2026 Number 2026 Weighted average exercise price (pence) 2025 Number 2025 Outstanding at the beginning of the year 3816 72,077 3544 77,281 Granted during the year 1582 118,953 - Forfeited during the year 3855 (1,349) - Exercised during the year - 1350 (5,204) Outstanding at the end of the year 2415 189,681 3816 72,077 2026 2025 Option pricing model used Black Scholes Black Scholes Issue price £13.50‐£38.50 £13.50‐£38.50 Exercise price £13.50‐£38.50 £13.50‐£38.50 Option life 10 years 10 years Expected volatility 2.63% 7.459% Fair value at measurement date £4.66 ‐ £26.91 £4.66 ‐ £26.91 Risk‐free interest rate 4.9% 1.5%
Page 48
The expected volatility for the options issued in the year to 30 June 2026 was based upon the volatilityover that 12 month period. For previous years it was based upon the historical volatility over the period since the Company’s shareswere listed on AIM. The expense recognised for share‐based payments during the year ended 30 June 2026 was £86,648(2025 : £89,223). The number of staff and officers holding share options as at 30 June 2026 was 16 (2025: 15). The shareoptions have been granted to underpin staff service conditions.
Page 50
During the year, there were no modifications to the terms and conditions of share‐basedpayment arrangements. 23. Earnings per share The weighted average number of shares in issue for the basic earnings per share calculation is5,224,860 (2025: 5,220,811) and for the diluted earnings per share, assuming the exercise of allshare options excluding the underwater options, is 5,302,036 (2025: 5,292,888). The calculation of the basic earnings per share is based on the profit for the period of £7,614,653(2025: £7,584,442) divided by the weighted average number of shares in issue of 5,224,860(2025: 5,220,811), the basic earnings per share is 145.74p (2025: 145.27p). The diluted earningsper share, assuming the exercise of all share options excluding the underwater options is basedon 5,302,036 (2025: 5,290,539 shares and is 143.62p (2025: 143.35p). 24. Pension commitments The Company operates a defined contribution pension scheme. The assets of the scheme areheld separately from those of the Company in an independently administered fund. The pensioncharge represents contributions payable by the Company to the fund and amounted to £95,876(2025: £91,942). No contributions were owing at the year end (2025: £nil). 25. Related party transactions During the year a dividend of £445,632 (2025: £466,428) was paid to a director and his wife. 26. Controlling party During the year there has not been an individual controlling party.
Page 51
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial ConductAuthority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution ofthis information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our PrivacyPolicy. END